{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:34:04Z","timestamp":1794641644254,"version":"4.9.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Resistance to B-cell\u2013targeted therapies in immune thrombocytopenia (ITP) has been linked to persistence of autoantibody-producing CD38+ long-lived plasma cells. CD38 antibody daratumumab has been proposed as a potential therapy for ITP. This multicenter, open-label, phase 2 study evaluated safety and efficacy of daratumumab in 21 patients with previously treated ITP. Following a safety run-in, 2 dosing cohorts received 8 and 10 subcutaneous injections of 1800 mg daratumumab weekly, respectively. Primary end points were safety and response (2 consecutive platelet counts \u226550 \u00d7 109\/L at week 12 for the safety run-in\/cohort 1, and at week 16 for cohort 2). At baseline, median platelet count was 17 \u00d7 109\/L, median number of prior therapies was 4. Most treatment-emergent adverse events were transient grade 1 to 2, most commonly infections (38%). Two patients (4.7%) experienced grade 3 adverse events, 1 infusion-related reaction, and 1 severe acute respiratory syndrome coronavirus 2 infection with acute renal failure. Ten patients (48%) met the primary efficacy end point. Sustained response (2 consecutive platelet counts \u226550 \u00d7 109\/L at week 24) was achieved in 8 patients (38%), of whom 2 later relapsed. Response and relapse rates did not differ between cohorts. Patient-reported quality of life measured by 36-Item Short-Form Health Survey improved in responding patients. Daratumumab decreased immunoglobulin levels in all patients, and substantially reduced CD38+ cells in peripheral blood and bone marrow. There was no significant difference in antiplatelet antibodies between responders and nonresponders. This study confirms CD38 as an important target in ITP. This trial was registered at clinicaltrials.gov as #NCT04703621, and at the European Clinical Trial Register (EudraCT #2019-004683-22).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017279","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:08:44Z","timestamp":1754420924000},"page":"143-154","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Safety and efficacy of daratumumab in immune thrombocytopenia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2656-2836","authenticated-orcid":false,"given":"Galina","family":"Tsykunova","sequence":"first","affiliation":[{"name":"1Department of Hematology-Oncology, \u00d8stfold Hospital Trust, Kalnes, Norway"},{"name":"2Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"3Division of Medicine, Department of Hematology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l Andre","family":"Holme","sequence":"additional","affiliation":[{"name":"2Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"4Department of Hematology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa Thi Tuyet","family":"Tran","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Akershus University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-0220","authenticated-orcid":false,"given":"Henrik","family":"Frederiksen","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Oslo University Hospital, Oslo, Norway"},{"name":"7Department of Internal Medicine, Thrombosis and Hemostasis Unit, \u00d8stfold Hospital Trust, Kalnes, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludvig A.","family":"Munthe","sequence":"additional","affiliation":[{"name":"8KG Jebsen Centre for B cell Malignancies and Precision Immunotherapy Alliance, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Drivet","sequence":"additional","affiliation":[{"name":"8KG Jebsen Centre for B cell Malignancies and Precision Immunotherapy Alliance, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassen","family":"Kared","sequence":"additional","affiliation":[{"name":"8KG Jebsen Centre for B cell Malignancies and Precision Immunotherapy Alliance, Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-1542","authenticated-orcid":false,"given":"Ingvild Hausberg","family":"S\u00f8rvoll","sequence":"additional","affiliation":[{"name":"9Norwegian National Unit for Platelet Immunology, Department of Laboratory Medicine, University Hospital of North Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Therese","family":"Ahlen","sequence":"additional","affiliation":[{"name":"9Norwegian National Unit for Platelet Immunology, Department of Laboratory Medicine, University Hospital of North Norway, Troms\u00f8, Norway"},{"name":"10Institute of Medical Biology, UiT The Arctic University of Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-1434","authenticated-orcid":false,"given":"Matthi\u00e9u","family":"Mah\u00e9vas","sequence":"additional","affiliation":[{"name":"11Service de M\u00e9decine Interne 1, Centre de R\u00e9f\u00e9rence des Cytop\u00e9nies Auto-Immunes de l'Adulte, Centre Hospitalo-Universitaire Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[{"name":"11Service de M\u00e9decine Interne 1, Centre de R\u00e9f\u00e9rence des Cytop\u00e9nies Auto-Immunes de l'Adulte, Centre Hospitalo-Universitaire Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2884-9247","authenticated-orcid":false,"given":"James","family":"Bussel","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-8810","authenticated-orcid":false,"given":"David J.","family":"Kuter","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Henrik","family":"Anderson Tvedt","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-6165","authenticated-orcid":false,"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[{"name":"1Department of Hematology-Oncology, \u00d8stfold Hospital Trust, Kalnes, Norway"},{"name":"2Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"10","key":"2026011309063418000_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011309063418000_bib2","doi-asserted-by":"crossref","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"EBioMedicine"},{"issue":"23","key":"2026011309063418000_bib3","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"9978","key":"2026011309063418000_bib4","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"2026011309063418000_bib5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2026011309063418000_bib6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"issue":"9","key":"2026011309063418000_bib7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.20951","article-title":"The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab","volume":"82","author":"Kuwana","year":"2007","journal-title":"Am J Hematol"},{"issue":"589","key":"2026011309063418000_bib8","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"issue":"25","key":"2026011309063418000_bib9","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2026011309063418000_bib10","doi-asserted-by":"crossref","first-page":"e003604","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"2026011309063418000_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"2026011309063418000_bib12","doi-asserted-by":"crossref","first-page":"102724","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"2026011309063418000_bib13","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2026011309063418000_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-022-05035-y","article-title":"Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab","volume":"102","author":"Str\u00fc\u00dfmann","year":"2023","journal-title":"Ann Hematol"},{"key":"2026011309063418000_bib15","doi-asserted-by":"crossref","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"2026011309063418000_bib16","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"2026011309063418000_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"2026011309063418000_bib18","author":"Ware","year":"1993"},{"key":"2026011309063418000_bib19","unstructured":"RAND\n          . 36-item short form survey (SF-36) scoring instructions. Accessed 25 October 2024. https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form\/scoring.html."},{"key":"2026011309063418000_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4419-9893-4_57","volume-title":"STOP, THAT and One Hundred Other Sleep Scales","author":"Shahid","year":"2011"},{"issue":"2","key":"2026011309063418000_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.25348","article-title":"Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent\/chronic immune thrombocytopenia: findings from the EXTEND study","volume":"94","author":"Khelif","year":"2019","journal-title":"Am J Hematol"},{"key":"2026011309063418000_bib22","doi-asserted-by":"crossref","first-page":"1296273","DOI":"10.3389\/fimmu.2024.1296273","article-title":"Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study","volume":"15","author":"Kared","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"2026011309063418000_bib23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood.V70.6.1722.1722","article-title":"Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies","volume":"70","author":"Kiefel","year":"1987","journal-title":"Blood"},{"issue":"2","key":"2026011309063418000_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.transci.2010.07.001","article-title":"Quantitative MAIPA: comparison of different MAIPA protocols","volume":"43","author":"Killie","year":"2010","journal-title":"Transfus Apher Sci"},{"issue":"23","key":"2026011309063418000_bib25","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2026011309063418000_bib26","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026011309063418000_bib27","article-title":"LB 01.1 - safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: interim results from a phase 2, randomized, double-blind, placebo-controlled study","author":"Kuter","year":"2024","journal-title":"ISTH"},{"issue":"3","key":"2026011309063418000_bib28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026011309063418000_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2026011309063418000_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/143\/2478673\/blooda_adv-2025-017279-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/143\/2478673\/blooda_adv-2025-017279-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:06:42Z","timestamp":1768313202000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/143\/546496\/Safety-and-efficacy-of-daratumumab-in-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017279","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2025,12,31]]}}}